Not All Seeds Are Created Equal
Cancer Treatment with Cesium-131 Brachytherapy Seeds by Isoray
Not all seed brachytherapy radioisotopes are the same. You and your doctor should choose the best isotope for your cancer treatment. Ask your doctor about Cesium-131 by Isoray.
Cs-131 has a higher average energy than any other commonly used prostate cancer brachytherapy isotope on the market. Energy is a key factor in how uniformly the radiation dose can be delivered throughout the prostate. (1)
Cs-131 has the shortest half-life of any commonly used prostate cancer brachytherapy isotope at 9.7 days. Cs-131 delivers 90% of the prescribed dose to the prostate gland in just 33 days compared to 58 days for Pd-103 and 204 days for I-125. (2)
Improved Coverage of the Prostate
Permanent prostate cancer brachytherapy utilizing Cs-131 seeds allows for better dose homogeneity and the sparing of the urethra and rectum while providing comparable prostate coverage compared to other seeds with comparable or fewer seeds and needles. (3, 4, 5, 6)
Rapid Resolution of Side effects
Studies demonstrate that objective measures of common prostate side-effects showing an early peak in symptoms in the 2-week to 1-month time frame. Resolution of morbidity resolved rapidly within 4-6 months. (7, 8, 9, 10)
Higher Biologically Effective Dose
Another benefit to the short half-life of Cs-131 is what is known as the “biological effective dose” or BED. Studies have shown Cs-131 is able to deliver a higher BED across a wide range of tumor types than either I-125 or Pd-103. (11)
Investigators tracking PSA in both single arm and randomized prostate cancer treatment trials have concluded Cs-131’s PSA response rates show similar early tumor control to I-125, long considered the gold standard in permanent seed brachytherapy. (8, 12, 13)
“Cesium makes a good doc an even better doc.”
Joe R. – San Fransisco, CA
WHY CESIUM-131 BY ISORAY?
With a shorter half-life and higher energy than other commonly used radioisotopes, Cesium-131 by Isoray has been shown to be a highly effective cancer treatment when planned appropriately. (10, 14, 17)
- Quick Recovery
- Speedy Return to PSA Baseline
Your Isotope Choice Makes a Difference
Cesium-131Introduced in 2004
9.7 Day Half Life
The amount of time for the radiation to half. A shorter half life means quicker to PSA baseline. (8, 12, 13)
The energy level of the isotope. Higher energy leads to greater coverage of the infected organ.
33 Days for 90% Dose
Faster dose delivery rate.
115 Gy Total Dose
The amount of dose. A lower dose means less total radiation used to treat your cancer.
Detectable in the body for 97 Days
Paladium-103Introduced in 1986
17 Day Half Life (18)
58 Days for 90% Dose
125 Gy Total Dose
Detectable in the body for 107 Days
Iodine-125Introduced in 1965
60 Day Half Life (18)
204 Days for 90% Dose
145 Gy Total Dose
Detectable in the body for 600 Days
Armpilla C, Dale R, Coles I, et al. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Rad Onc Biol Phys 2003; 55:378-385.
Learn about how Cesium-131 by Isoray is being used in radiation treatment.
Doctors around the country use Cesium-131 by Isoray to treat a wide range of cancers.
Over 10,000 patients treated.
A novel approach for radiation delivery.
An innovative solution for recurrent cancers.
Head & Neck
Delivering personalized radiation to tightly controlled areas.
Customized individual cancer treatment.
Breakthroughs in brachytherapy by Cesium Pioneers.
Doctors across the US are using Cesium-131 by Isoray in powerful ways with great outcomes. Check out their work.
The ability to deliver high concentrated radiation treatment in a tightly controlled area at the time of surgery really allows us to customize and individualize cancer treatment for our patients.Dr. Adam J. Luginbuhl, MD
1. Prestidge B.R., Bice W.S., Jurkovic I., et al. Cesium-131 Permanent Prostate Brachytherapy: An Initial Report. Int. J. Radiation Oncology Biol. Phys. 2005: 63 (1) 5336-5337.
2. Neill B, et al. The Nature and Extent of Urinary Morbidity in Relation to Prostate Brachytherapy Urethral Dosimetry. Brachytherapy 2007:6(3)173-9.
3. Musmacher JS, et al. Dosimetric Comparison of Cesium-131 and Palladium-103 for Permanent Prostate Brachytherapy. Int. J. Radiation Oncology Biol. Phys. 2007:69(3)S730-1.
4. Yaparpalvi R, et al. Is Cs-131 or I-125 or Pd-103 the “Ideal” Isotope for Prostate Boost Brachytherapy? A Dosimetric View Point. Int. J. Radiation Oncology Biol. Phys. 2007:69(3)S677-8.
5. Sutlief S, et al. Cs-131 Prostate Brachytherapy and Treatment Plan Parameters. Medical Physics 2007:34(6)2431.
6. Yang R, et al. Dosimetric Comparison of Permanent Prostate Brachytherapy Plans Utilizing Cs-131, I-125 and Pd-103 Seeds. Medical Physics 2008:35(6)2734.
7. Prestidge B, et. al. Clinical Outcomes of a Phase-II, Multi-institutional Cesium-131 Permanent Prostate Brachytherapy Trial. Brachytherapy. 2007: 6 (2)78.
8. Moran B, et al. Cesium-131 Prostate Brachytherapy: An Early Experience. Brachytherapy 2007:6(2)80.
9. Jones A, et al. IPSS Trends for Cs-131 Permanent Prostate Brachytherapy. Brachytherapy 2008:7(2)194.
10. DeFoe SG, et al. Is There Decreased Duration of Acute Urinary and Bowel Symptoms after Prostate Brachytherapy with Cesium 131 Radioisotope? Int. J. Radiation Oncology Biol. Phys. 2008:72(S1)S317.
11. Armpilia CI, Dale RG, Coles IP et al. The Determination of Radiobiologically Optimized Half-lives for Radionuclides Used in Permanent Brachytherapy Implants. Int. J. Radiation Oncology Biol. Phys. 2003; 55 (2): 378-385.
12. Bice W, et. al. Recommendations for permanent prostate brachytherapy with 131Cs: a consensus report from the Cesium Advisory Group. Brachytherapy 2008:7(4)290-296.
13. Platta CS, et al. Early Outcomes of Prostate Seed Implants with 131Cs: Toxicity and Initial PSA Dynamics from a Single Institution. Int. J. Radiation Oncology Biol. Phys. 2008:72(S1)S323-4.
14. Tomaszewski JJ, et al. Cesium 131 versus iodine 125 implants for prostate cancer: evaluation of early PSA response. The Canadian Journal of Urology. 2010;17(5): 5360-5364.
15. R.M. Benoit, R.P. Smith, S. Beriwal. Five Year Prostate-specific Antigen Outcomes after Caesium Prostate Brachytherapy. Clinical Oncology. 26 (2014) 776 780.
16. Brian J. Moran, MD, Michelle H. Braccioforte, MPH. Prostate Cancer Foundation of Chicago, Westmont, IL. PSA Outcomes in a Single Institution, Prospective Randomized 131Cs/125I Permanent Prostate Brachytherapy Trial Abstracts / Brachytherapy. 13 (2014) S15eS126.
17. Amit B. Shah, MD, Arnav A. Shah, Gregory A. Fortier, MD. Radiation Oncology, York Cancer Center, Wellspan Health, York, PA. A Comparison of AUA Symptom Scores following Permanent Low-Dose-Rate Prostate Brachytherapy with Iodine-125 and Cesium-131, Abstracts / Brachytherapy 12 (2013) S11eS77.
18. Herstein A, Wallner K, Merrick G, Mitsuyama H, Armstrong J, True L, Cavanagh W, Butler W. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial. Cancer J. 2005 Sep-Oct;11(5):385-9.